{
    "code": "52026204",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52026204",
    "time": "2019-01-25 03:23:31",
    "許可證字號": "衛部藥輸字第026204號",
    "註銷狀態": "已註銷",
    "註銷日期": "105\/12\/23",
    "註銷理由": "自請註銷",
    "有效日期": "107\/12\/02",
    "發證日期": "102\/12\/02",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA05202620405",
    "中文品名": "維取力",
    "英文品名": "Victrelis 200mg capsule",
    "適應症": "Victrelis (boceprevir)適用於與peginterferon alfa及ribavirin併用，治療先前未曾接受治療或先前曾以interferon及ribavirin治療失敗(包括對先前治療無反應、部分反應及復發)之代償性肝病(包含肝硬化)成人患者(18歲及以上)的慢性C型肝炎基因型第1型感染症。",
    "劑型": "130膠囊劑",
    "包裝": "24-1000粒鋁箔盒裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "主成分略述": [
        "Boceprevir"
    ],
    "限制項目": "02輸　入 1EPhase IV Study",
    "申請商名稱": "0929301100  美商默沙東藥廠股份有限公司台灣分公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F390012100  MSD INTERNATIONAL GMBH  (SINGAPORE BRANCH)",
        "製造廠廠址": "70 TUAS WEST DRIVE, SINGAPORE 638414",
        "製造廠公司地址": ""
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "次製造廠": [
        {
            "製造廠名稱": "F050006000  SCHERING-PLOUGH LABO N.V.",
            "製造廠廠址": "INDUSTRIEPARK 30, B-2220 HEIST-OP-DEN-BERG, BELGIUM",
            "製造廠公司地址": "",
            "製造廠國別": "BELGIUM",
            "製程": "包裝及分裝"
        }
    ],
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "0818004500",
            "成分名稱": "Boceprevir",
            "含量描述": "",
            "含量": "200.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "02026204001-104-04-10.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026204&Seq=002&Type=9"
        },
        {
            "title": "Victrelis 200mg Capsule Foil_Page_1-104-08-25(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026204&Seq=007&Type=8"
        }
    ]
}